2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
复制标题
DOI：
10.1016/j.cardfail.2017.04.014
复制
发表时间：
2017-08-08
期刊：
影响因子：
37.8
通讯作者：
Westlake, Cheryl
中科院分区：
文献类型：
--
作者：
Yancy, Clyde W.;Jessup, Mariell;Westlake, Cheryl
本次重点更新的目的是更新“2013年ACCF/AHA心力衰竭管理指南”（9）（2013年HF指南）中自发表以来出现新证据的领域。对于此次更新和未来的心力衰竭（HF）指南，美国心力衰竭协会（HFSA）与ACC和AHA合作，提供了关于HF管理的协调指导。重点更新的范围包括对生物标志物部分的修订;射血分数降低（HFrEF）的C期HF的新疗法;射血分数保留（HFpEF）的HF更新;关于重要合并症的新数据，包括睡眠呼吸暂停、贫血和高血压;以及对预防HF的新见解。
The purpose of this focused update is to update the “2013 ACCF/AHA Guideline for the Management of Heart Failure”(9)(2013 HF guideline) in areas in which new evidence has emerged since its publication. For this update and future heart failure (HF) guidelines, the Heart Failure Society of America (HFSA) has partnered with the ACC and AHA to provide coordinated guidance on the management of HF.The scope of the focused update includes revision to the sections on biomarkers; new therapies indicated for stage C HF with reduced ejection fraction (HFrEF); updates on HF with preserved ejection fraction (HFpEF); new data on important comorbidities, including sleep apnea, anemia, and hypertension; and new insights into the prevention of HF.